Sandoz is a world leader in generic pharmaceuticals, finding innovative ways to making medicines affordable and accessible to more than 90 percent of the world’s population.Learn more about our company
Visions and Values
Sandoz receives FDA approval for Glatopa™ as the first generic competitor to MS therapy Copaxone® 20mg
This approval reinforces Sandoz leadership in complex, differentiated generic products.
July 28, 2015
Sandoz today announced the US market introduction of its budesonide inhalation suspension, a generic version of Pulmicort Respules® (budesonide) inhalation suspension 1 mg strength by AstraZeneca LP....
Our people are our greatest resource. We are always looking for new colleagues to share in our commitment to make the world a healthier place.Learn more about careers at Sandoz
Watch our videos to discover more about the world of Sandoz and the generics market.Visit our video gallery to watch the latest episode